The Highest Grade of Cells.
The Ultimate Therapeutic Outcome.
VetBioLab manufactures premium Equine and Human-derived UC-MSCs and Exosomes. Because we originate from human clinical biotechnology, our manufacturing criteria supersedes current veterinary industry requirements.
Why Cell Grade Dictates Efficacy
In regenerative medicine, the therapeutic payload is entirely dependent on the vitality, purity, and secretome profile of the administered cells. Veterinary clinics often rely on autologous systems or lower-tier allogeneic processing, resulting in high variability.
VetBioLab is clinical. By applying human GMP standard operating procedures—including strict Population Doubling Limits (PDL) and metabolic flow cytometry—we guarantee a hyper-potent, standardized product capable of massive immunomodulation.
Low Passage Cryopreservation
Cells are harvested and banked at Passage 2 or 3, preserving telomere length and preventing senescence, ensuring maximum paracrine activity upon injection.
Secretome Validation (PGE2 & TSG-6)
Every batch is quantified for potent anti-inflammatory cytokines. We do not release batches that fall below human-grade therapeutic thresholds.
Potency vs. Production Standard
Benchmarking VetBioLab against standard veterinary allogeneic metrics.
Comprehensive Biologic Portfolio
VetBioLab uniquely offers both strictly species-matched therapies and advanced xenogeneic solutions to address the full spectrum of clinical veterinary needs.
Equine UC-MSCs
Derived from premium equine umbilical cord tissue. Processed under human-equivalent GMP protocols to yield a highly concentrated, species-matched therapeutic for conservative clinical practices and strict regulatory jurisdictions.
- ✓ Optimal for elite sporting horses
- ✓ Zero donor-site morbidity (vs Autologous)
- ✓ High expression of iNOS pathway modulators
Human hUC-MSCs & Exosomes
The frontier of veterinary longevity. Utilizing immune-privileged human Wharton's Jelly MSCs and cell-free exosomes to achieve unprecedented immunomodulation in companion animals and horses, leveraging the highly potent IDO pathway.
- ✓ Superior vitality and population doubling
- ✓ Exosomes provide 'Zero-Flare' joint injections
- ✓ Intense downregulation of IFN-γ and TNF-α
Validating the Clinical Model
The regulatory landscape for veterinary biologics is rapidly maturing. The EMA authorization of DogStem (an equine-derived MSC product for canine osteoarthritis) successfully established the regulatory predicate for both allogeneic and xenogeneic therapies.
DogStem received approvals for cross-species use by demonstrating safety and profound efficacy. VetBioLab is looking to follow and accelerate these same steps. Because our operations are deeply clinical and backed by human-grade manufacturing, we possess the institutional ability, data, and infrastructure to execute pivotal field trials and achieve regulatory compliance globally.
Our Clinical Commitment:
- • Conducting GLP-compliant Target Animal Safety (TAS) studies.
- • Executing multi-center, double-blind efficacy trials.
- • Partnering with regulatory bodies (USDA, EMA, ICA) for market authorization.
Interactive Clinical Data
Explore the simulated efficacy and biomarker trajectories based on established xenogeneic and allogeneic literature. Select a patient species to review corresponding technical metrics.
Equine Sports Medicine
Treating complex suspensory ligament desmitis and degenerative joint disease. Utilizing our Equine UC-MSCs or Human Exosomes allows for deep tissue penetration, rapid downregulation of pro-inflammatory cytokines, and robust type I collagen synthesis without the risks associated with bone marrow aspiration.
- ↑ Upregulation of IL-10 & TGF-β
- ↓ Suppression of MMP-13 (Cartilage degradation)
- ↑ Sustained PGE2 Secretion over 72h
Structural Integrity Trajectory (Lesion Healing)
Simulated percentage of lesion healing via ultrasound assessment over 12 weeks.
📚 Clinical Evidence Base
Safety and efficacy of equine MSCs in canine OA.
Punzón et al., (2022). Validates the allogeneic & xenogeneic pathway (DogStem foundation).
Evaluation of Curative Effect of Human UC-MSCs in Dogs.
Zhang et al., (2018). Demonstrates safety, immune evasion, and efficacy of human cells in veterinary patients.
Exosomes derived from hUC-MSCs alleviate osteoarthritis.
Wang et al., (2019). Establishes the mechanism of action for Exosome-mediated cartilage repair.
VetBioLab Partner Portal
Select your organization type to access product catalogs, clinical protocols, or territory rights.